Jane Street
KYTX icon

Jane Street’s Kyverna Therapeutics KYTX Stock Holding History

Jane Street’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Buy
+27,500
New +$244K ﹤0.01% 9653
2026
Q1 		– Sell
-54,800
Closed -$515K – 13204
2025
Q4 		$515K Buy
+54,800
New +$407K ﹤0.01% 7615

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Jane Street's KYTX Position: Q2 2026 in Review

Jane Street reduced its Kyverna Therapeutics (KYTX) stake by 83% in Q2 2026, selling an estimated $771K and leaving 17,314 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #10325.

Jane Street first reported a position in KYTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.71M in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Jane Street held 17,314 shares of Kyverna Therapeutics worth $154K as of Q2 2026.
  • Jane Street sold 86,900 Kyverna Therapeutics shares in Q2 2026, an estimated $771K.
  • Kyverna Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10325 holding.
  • Jane Street first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Jane Street's Kyverna Therapeutics position peaked at $1.71M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.